INT345374

Context Info Confidence 0.01 First Reported 2010 Last Reported 2010 Negated 0 Speculated 0 Reported most in Body Documents 1 Total Number 2 Disease Relevance 2.95 Pain Relevance 0

cytoplasm (VEGFA, Flt4) extracellular space (VEGFA) growth (VEGFA) extracellular region (VEGFA) proteinaceous extracellular matrix (VEGFA) plasma membrane (Flt4)

Anatomy Link Frequency endothelial cells 2 VEGFA (Homo sapiens) Flt4 (Mus musculus)

Pain Link Frequency Relevance Heat antagonist 4 36.56 imagery 12 5.00 anesthesia 6 5.00 isoflurane 6 5.00

Disease Link Frequency Relevance Heat Cancer 230 94.88 Metastasis 124 93.88 Breast Cancer 12 83.84 Lymphatic Metastasis 4 75.76 Immunotherapy Of Cancer 2 63.16 Recurrence 2 53.76 Advanced Or Metastatic Breast Cancer 4 51.48 Malignant Neoplastic Disease 6 51.00 Hyperplasia 2 40.32 Injury 2 27.36

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

In addition, VEGFR-3, the VEGF-C receptor, is predominantly expressed on lymphatic endothelial cells [29], and VEGF-C-dependent activation of VEGFR-3 stimulates the growth of lymphatic endothelial cells and lymphatics [30].

VEGF Positive_regulation (activation) of VEGFR-3 in endothelial cells

1) Confidence 0.01 Published 2010 Journal BMC Med Section Body Doc Link PMC2989928 Disease Relevance 1.75 Pain Relevance 0

The growth of blood vessels (angiogenesis) is primarily initiated by activation of VEGFR-1 and VEGFR-2 by VEGF-A, whereas lymphangiogenesis is predominantly driven by VEGF-C, which activates VEGFR-2 and VEGFR-3 expressed in lymphatic endothelial cells.

VEGF Positive_regulation (activates) of VEGFR-3 in endothelial cells

2) Confidence 0.01 Published 2010 Journal BMC Med Section Body Doc Link PMC2989928 Disease Relevance 1.20 Pain Relevance 0

General Comments

This test has worked.